UNSPSC 51111820: Letrozole

This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C17H11N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LKK855W8I, chemically known as 4,4-(1h-1,2,4-triazol-1-ylmethylene)dibenzonitrile but generally known as letrozole, which bears US NIH Compound Identifier 3902. European Medicines Agency schedules Letrozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08444MIG.

UNSPSC 51111820 Letrozole is a Commodity code covering the procurement of this aromatase inhibitor pharmaceutical, used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. State and local governments purchase letrozole through health departments, public health agencies, correctional health systems, and state Medicaid programs that supply the drug to eligible patients or incarcerated populations. The drug is typically solicited as part of broader pharmaceutical procurement contracts or as a standalone item through competitive bidding processes, often with volume-based pricing or rebate structures negotiated at the state or regional level.

The source provides no recent state and local contract opportunities tagged to this code.